LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Peptide from Umbilical Cord Blood Shuts Down a Neutrophil Inflammatory Factor

By LabMedica International staff writers
Posted on 19 Sep 2016
Image: Infection fighting cells from umbilical cord blood (left) and circulating blood three days after birth (right) from the same prematurely born baby. Umbilical cord blood has high levels of neonatal NET inhibitory factor (nNIF), which inhibits formation of neutrophil extracellular traps (NETs) (Photo courtesy of Mark Cody/Diana Lim, University of Utah Health Care).
Image: Infection fighting cells from umbilical cord blood (left) and circulating blood three days after birth (right) from the same prematurely born baby. Umbilical cord blood has high levels of neonatal NET inhibitory factor (nNIF), which inhibits formation of neutrophil extracellular traps (NETs) (Photo courtesy of Mark Cody/Diana Lim, University of Utah Health Care).
Researchers have isolated a peptide in umbilical cord blood that blocks the formation of neutrophil extracellular traps (NETs) and reduces inflammation and risk of developing sepsis.

NETs are molecular lattices of decondensed chromatin embedded with histones, granule enzymes, and antimicrobial peptides that are extruded by immune system neutrophil granulocytes, (polymorphonuclear leukocytes or PMNs) to capture and contain bacteria, viruses, and other pathogens. Experimental evidence has indicated that NETs also cause inflammatory vascular and tissue damage, suggesting that identifying pathways that inhibit NET formation may have therapeutic implications.

After examining various potential sites for the presence of a NET inhibitor, investigators at University of Utah Health Care (Salt Lake City, USA) discovered a peptide in umbilical cord blood that inhibited NET formation in vitro and in vivo and that appeared to be an endogenous regulator of NET generation.

They reported in the September 6, 2016, online edition of The Journal of Clinical Investigation that in addition to this neonatal NET-inhibitory factor (nNIF), they had also identified additional nNIF-related peptides (NRPs) that inhibited NET formation. These nNIFs and NRPs blocked NET formation induced by pathogens, microbial toxins, and pharmacologic agonists in vitro and in mouse models of infection and systemic inflammation, and they improved mortality in mouse models of systemic inflammation.

"We found something we were not expecting, and it has taken us to new strategies for therapy that did not exist before," said senior author Dr. Guy Zimmerman, professor of internal medicine at University of Utah Health Care.

Related Links:
University of Utah Health Care

Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Clinical Informatics Platform
CLARION™

Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more